Latanoprost ophthalmic solution 0.005%

DRUG9 trials

Conditions

Glaucoma, Open-AngleOcular HypertensionOpen Angle GlaucomaOpen-angle GlaucomaPrimary Open Angle GlaucomaPrimary Open Angle Glaucoma or Ocular HypertensionPrimary Open Angle Glaucoma, Ocular Hypertension

Phase 2

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

CompletedNCT01731002

Aerie PharmaceuticalsOcular Hypertension, Open Angle Glaucoma

Start: 2012-11-30End: 2013-05-31Updated: 2018-04-17

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

CompletedNCT02057575

Aerie PharmaceuticalsOcular Hypertension, Open Angle Glaucoma

Start: 2014-01-31End: 2014-06-30Updated: 2019-06-04

Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

CompletedNCT02179008

Santen Inc.Ocular Hypertension, Open-angle Glaucoma

Start: 2014-06-30End: 2015-01-31Updated: 2018-04-18

A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-

CompletedNCT02623738

Santen Pharmaceutical Co., Ltd.Ocular Hypertension, Primary Open Angle Glaucoma

Start: 2015-12-06End: 2017-02-10Updated: 2017-11-20

Phase 3

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

CompletedNCT02558400

Aerie PharmaceuticalsOcular Hypertension, Open-angle Glaucoma

Start: 2015-09-18End: 2017-06-30Updated: 2019-06-04

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

CompletedNCT02674854

Aerie PharmaceuticalsOcular Hypertension, Open-angle Glaucoma

Start: 2016-02-29End: 2017-03-31Updated: 2019-05-21

A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study

CompletedNCT02822742

Santen Pharmaceutical Co., Ltd.Primary Open Angle Glaucoma or Ocular Hypertension

Start: 2016-07-02End: 2017-04-28Updated: 2017-11-20

A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

CompletedNCT05495061

Santen Pharmaceutical Co., Ltd.Primary Open Angle Glaucoma, Ocular Hypertension

Start: 2022-08-09End: 2023-04-18Updated: 2023-12-05

Phase 4

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

CompletedNCT01253902

AllerganGlaucoma, Open-Angle, Ocular Hypertension

Start: 2010-12-31End: 2011-10-31Updated: 2012-11-07

2020-06-2240 citations

Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.

2020-06-1075 citations

Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2

Advances in Therapy2020-03-1284 citations

Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2.

2020-01-2414 citations

Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

Journal of Glaucoma2019-03-0550 citations

Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension

British Journal of Ophthalmology2015-07-24101 citations

Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension

Current Medical Research and Opinion2013-09-0579 citations

Latanoprost ophthalmic solution 0.005%

Sponsors

Conditions

Phase 2

Phase 3

Phase 4

Related Papers